Drug Profile


Alternative Names: BAY 102; BAY-1021189; MK-1242

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals; Merck & Co
  • Class Carbamates; Fluorobenzenes; Heart failure therapies; Pyrazoles; Pyridines; Pyrimidines; Small molecules; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic heart failure
  • Phase I Coronary artery disease

Most Recent Events

  • 28 Feb 2017 Merck has patent protection for vericiguat in USA (Merck Annual report 2016)
  • 30 Sep 2016 Phase-III clinical trials in Chronic heart failure in Germany, Hungary and Spain (PO) (EudraCT2016-000671-25)
  • 01 Sep 2016 Phase-III clinical trials in Chronic heart failure in Israel (PO) (NCT02861534)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top